Top

Published in:

Open Access 01-12-2012 | Poster presentation

MiRs in RA: possible biomarkers and therapeutic targets

Authors: Maria Filkova, Caroline Ospelt, Joanna Stanczyk, Serena Vettori, Ladislav Senolt, Mojca Frank, Christoph Kolling, Beat A Michel, Renate E Gay, Steffen Gay, Astrid Jüngel

Published in: Arthritis Research & Therapy | Special Issue 1/2012

Excerpt

New concepts of therapy highlight an early use of effective treatment to prevent further joint damage in RA. Altered expression of epigenetic marks like miRs offers us the possibility to develop new diagnostic tools and novel therapeutic targets. …

Stanczyk J, Ospelt C, Karouzakis E, Filer A, Raza K, Kolling C, Gay R, Buckley CD, Tak PP, Gay S, Kyburz D: Altered expression of microRNA-203 in rheumatoid arthritis synovial fibroblasts and its role in fibroblast activation. Arthritis Rheum. 2011, 63: 373-81. 10.1002/art.30115.PubMedCentralCrossRefPubMed

Stanczyk J, Pedrioli DM, Brentano F, Sanchez-Pernaute O, Kolling C, Gay RE, Detmar M, Gay S, Kyburz D: Altered expression of MicroRNA in synovial fibroblasts and synovial tissue in rheumatoid arthritis. Arthritis Rheum. 2008, 58: 1001-9. 10.1002/art.23386.CrossRefPubMed

Pauley KM, Satoh M, Chan AL, Bubb MR, Reeves WH, Chan EK: Upregulated miR-146a expression in peripheral blood mononuclear cells from rheumatoid arthritis patients. Arthritis Res Ther. 2008, 10: R101-10.1186/ar2344.PubMedCentralCrossRefPubMed

Fulci V, Scappucci G, Sebastiani GD, Giannitti C, Franceschini D, Meloni F, Colombo T, Citarella F, Barnaba V, Minisola G, Galeazzi M, Macino G: miR-223 is overexpressed in T-lymphocytes of patients affected by rheumatoid arthritis. Hum Immunol. 2010, 71: 206-11. 10.1016/j.humimm.2009.11.008.CrossRefPubMed

Title: MiRs in RA: possible biomarkers and therapeutic targets
Authors: Maria Filkova
Caroline Ospelt
Joanna Stanczyk
Serena Vettori
Ladislav Senolt
Mojca Frank
Christoph Kolling
Beat A Michel
Renate E Gay
Steffen Gay
Astrid Jüngel
Publication date: 01-12-2012
Publisher: BioMed Central
Published in: Arthritis Research & Therapy / Issue Special Issue 1/2012
Electronic ISSN: 1478-6362
DOI: https://doi.org/10.1186/ar3615

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Special Issue 1/2012

Anti-TNF antibody therapy induces IL-17 suppressing regulatory T cells in patients with rheumatoid arthritis

Understanding the role of Fas-Fas ligand system in bone

The bacterial effector protein YopM reduces rheumatoid arthritis (RA) outcome by inhibiting inflammation and bone destruction

Angiogenesis in rheumatoid arthritis: the role of fut 1

Regulation of macrophage-mediated chronic inflammation by JAK inhibitors

Combined effects of the hedgehog pathway inhibitor LDE225 and nilotinib in a random mutagenesis screen

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials